title: Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.
abstract: BACKGROUND
  Structured interruptions of antiretroviral therapy of HIV-1 infected individuals are currently being tested in clinical trials to study the effect interruptions have on the immune responses and control of virus replication.
  
  
  OBJECTIVE
  To investigate the potential risks and benefits of interrupted therapy using standard population dynamical models of HIV replication kinetics.
  
  
  METHODS
  Standard population dynamical models were used to study the effect of structured therapy interruptions on the immune effector cells, the latent cell compartment and the emergence of drug resistance.
  
  
  CONCLUSIONS
  The models suggest that structured therapy interruption only leads to transient or sustained virus control if the immune effector cells increase during therapy. This increase must more than counterbalance the increase in susceptible target cells induced by therapy. The risk of inducing drug resistance by therapy interruptions or the risk of repopulating the pool of latent cells during drug-free periods may be small if the virus population remains at levels considerably below baseline. However, if the virus load increases during drug-free periods to levels similar to or higher than baseline before therapy, both these risks increase dramatically.
authors.affiliation: Friedrich Miescher Institut, Basel, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Bonhoeffer
authors.forename: M
authors.initials: M
authors.lastname: Rembiszewski
authors.forename: G M
authors.initials: GM
authors.lastname: Ortiz
authors.forename: D F
authors.initials: DF
authors.lastname: Nixon
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D008962:Models, Theoretical; D018570:Risk Assessment; D013602:T-Lymphocytes, Cytotoxic; D017735:Virus Latency
chemical_list: D019380:Anti-HIV Agents